There are 2789 resources available
933P - Updated results for pembrolizumab (pembro) monotherapy as first-line therapy for advanced hepatocellular carcinoma (HCC) in the phase II KEYNOTE-224 study
Presenter: Jean-Luc van Laethem
Session: ePoster Display
934P - The TARGET study: A global investigation of advanced dosimetry for transarterial radioembolization of hepatocellular carcinoma with yttrium-90 glass microspheres
Presenter: Marnix Lam
Session: ePoster Display
935P - An exploratory subgroup analysis of a phase II/III trial of donafenib versus sorafenib in the first-line treatment of advanced hepatocellular carcinoma
Presenter: Feng Bi
Session: ePoster Display
936P - Effects of tislelizumab (TIS) monotherapy on health-related quality of life in patients with previously treated unresectable hepatocellular carcinoma (HCC)
Presenter: Zhenggang Ren
Session: ePoster Display
937P - Multicenter phase II trial of lenvatinib plus hepatic intra-arterial infusion chemotherapy with cisplatin for advanced hepatocellular carcinoma: LEOPARD
Presenter: Masafumi Ikeda
Session: ePoster Display
939P - Phase II study of pembrolizumab (pembro) and bavituximab (bavi) in advanced hepatocellular carcinoma (HCC)
Presenter: David Hsiehchen
Session: ePoster Display
940P - Dose-escalation trial of OBP-301, novel telomerase-specific oncolytic virus in advanced hepatocellular carcinoma
Presenter: Jeong Heo
Session: ePoster Display
941P - Neoadjuvant radiotherapy improves overall survival in patients with resectable hepatocellular carcinomas
Presenter: Zhiwen Luo
Session: ePoster Display
Resources:
Abstract